General Considerations for the Use of New Approach Methodologies in Drug Development: Draft Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
March 18, 2026
March 18, 2026
090afb3a-8fce-4ac8-ac78-d208784d28ff
Related Documents
Establishing Impurity Specifications for Antibiotics
Guidance DocumentApril 20, 2026Center for Drug Evaluation and Research
New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers
Guidance DocumentMarch 3, 2026Center for Drug Evaluation and Research
Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics
Guidance DocumentNovember 15, 2024Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox